Phase 3 Trial of Selpercatinib in Advanced <i>RET</i> -Mutant Medullary Thyroid Cancer

2023169 citationsJournal Article

Authors

Julien Hadoux · University of Pisa

Rossella Elisei · University of Pisa

Marcia S. Brose · University of Pisa

Ana O. Hoff · University of Pisa

Bruce G. Robinson · University of Pisa

Ming Gao · University of Pisa

Barbara Jarząb · University of Pisa

Abstract

Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with <i>RET</i>-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.).

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 20, pp. 1851-1861

DOI: 10.1056/nejmoa2309719

Field-Weighted Citation Impact: 33.84